Emil Sundberg

Dr. Emil Sundberg


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
ESEmil Sundberg
Emil Sundberg
THTove Hoffman
Tove Hoffman
ANAnna Nilsson
Anna Nilsson
SPSimon Pahnke
Simon Pahnke
GEGunilla Enblad
Gunilla Enblad
JPJosefine Palle
Josefine Palle
Background: Children develop symptomatic coronavirus disease 2019 (COVID‐19) more rarely than adults upon infection with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Pediatric oncology and hematology patients may be at increased risk of severe COVID‐19 due to their underlying disease or treatment. We investigated COVID‐19 and seroprevalence of anti‐SARS‐CoV‐2 antibodies, respectively, in a Swedish cohort of pediatric oncology and hematology patients.Procedure: Patients (n = 136) were recruited between June 2020 and September 2021 at Uppsala University Children's Hospital, Sweden. Up to six consecutive blood samples per patient were analyzed for wild‐type anti‐S1 IgM and IgG antibodies (including after vaccination, n = 4). Clinical data on COVID‐19 (including polymerase chain reaction [PCR] test results) were collected from electronic medical records. A questionnaire was completed at recruitment.Results: A cumulative seroprevalence (IgM and IgG) of 33% (45/136 patients, 95% confidence interval: 25%–41%) was observed in this patient cohort, of whom 66% (90/136 patients) were under severe immunosuppressive treatment during the study period. Increasing patient age (p = .037) and PCR test results (p < .002) were associated with seropositivity in nonvaccinated cases. Most seropositive, nonvaccinated cases (32/43, 74%) were never PCR‐verified for SARS‐CoV‐2 infection. Of the 13 patients with PCR‐verified infection, nine (69%) reported mild disease. A majority (63%) reported continued school attendance during the pandemic.Conclusions: Swedish pediatric oncology and hematology patients developed antibodies against SARS‐CoV‐2, despite their diagnosis and/or treatment, and the observed seroprevalence was similar to that in national pediatric outpatients. PCR‐verified cases underestimate the true incidence of COVID‐19 in this patient cohort.

Verified
Journal Article
Open access
PDF file
ETEva Tiselius
Eva Tiselius
ESEmil Sundberg
Emil Sundberg
HAHanna Andersson
Hanna Andersson
AHAnna Höbinger
Anna Höbinger
PJPeter Jahnmatz
Peter Jahnmatz
SHShanie Hedengren
Shanie Hedengren
Severe haematological diseases and lymphoid malignancies require bone marrow (BM)-suppressive treatments. Knowledge regarding the impact of BM-suppressive treatments on children’s memory T cells is very limited. Memory T cells play a crucial role in defending against herpesviruses, which is particularly relevant in paediatric cancer care. We studied 53 children in total; 34 with cancer and 2 with severe haematological disorders, with some receiving BM-suppressive treatment with or without allogeneic–haematopoietic stem cell transplantation (allo-HSCT), alongside 17 healthy controls. We focused on peripheral blood proportions of memory T-cell subsets using flow cytometry and analysed cytokine-secreting T cells with a four-parameter FluoroSpot assay in response to T-cell mitogen and varicella zoster virus (VZV) peptides. Patients on BM-suppressive treatment showed increased clusters of differentiation (CD)4+ and CD8+ effector memory (TEM)/terminally differentiated effector (TEFF) T cells compared to the healthy controls. They also exhibited, amongst other things, when compared to the healthy controls, a reduced total number of cytokine-secreting cells, by means of interferon (IFN)-γ, interleukin (IL)-17A, IL-10, and IL-22, following mitogen activation. A diminished IFN-γ response among the children with BM-suppressive treatment was observed upon VZV-peptide stimulation, compared to the healthy children. Collectively, the findings herein indicate that the children who are undergoing or have finished BM-suppressive treatment display qualitative differences in their T-cell memory compartment, potentially increasing their susceptibility to severe viral infections and impacting their immunotherapy, which relies on the functional ability of autologous T cells.